Release Date
December 10, 2011
|
Expiration Date
December 10, 2012 |
|
| Faculty |
Edith Perez, MD
Mayo Clinic
Jacksonville, Florida, United States
Hope S. Rugo, MD
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, California, United States
Sunil Verma, MD, MSEd, FRCPC
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada
|
|
|
Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with breast cancer. |
Overview
This CME-certified interview discusses recently released data from the 2011 Annual Breast Cancer Meeting in San Antonio on various aspects of the management of patients with breast cancer. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Summarize the most recent clinical trial data regarding novel therapeutic options for the management of breast cancer, and outline best strategies for the integration of these therapies into clinical practice
- Compare and contrast the efficacy and tolerability of various therapies and therapeutic combinations available for the treatment of breast cancer
- Interpret and integrate recent clinical trial data into improved patient management strategies
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council of Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. |
Credit Designation Statement
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each module may provide the following credits:
Module 1 [2011613-01—Verma/Rugo]: 0.5 credit hours*
Module 2 [2011613-02—Verma/Perez]: 0.25 credit hours*
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the video player pages.
|
Support Statement
This activity is supported by an unrestricted educational grant from Novartis Oncology. |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME Activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Perez has declared that she has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rugo has disclosed that she has received consulting fees from Genomic Health. She has performed contracted research (funding directed to CALGB or UCSF) for BMS, Celgene, and Eisai. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Verma has disclosed that he has performed research support for Roche and Sanofi-Aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Amy Furedy, RN, OCN (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
